Lv1
95 积分 2021-05-18 加入
Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer
9天前
已完结
Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering
9天前
已完结
A logic-gated trispecific engager enhances macrophage killing of cancer cells in solid tumors
9天前
已完结
Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study
14天前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
15天前
已完结
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
15天前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
15天前
已完结
Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer
16天前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
17天前
已完结
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
21天前
已完结
皖公网安备34019202002308
